EA200500054A1 - NEW CONNECTIONS APPLICABLE FOR THE TREATMENT OF OBESITY, DIABETES MELLITUS TYPE II AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM - Google Patents

NEW CONNECTIONS APPLICABLE FOR THE TREATMENT OF OBESITY, DIABETES MELLITUS TYPE II AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM

Info

Publication number
EA200500054A1
EA200500054A1 EA200500054A EA200500054A EA200500054A1 EA 200500054 A1 EA200500054 A1 EA 200500054A1 EA 200500054 A EA200500054 A EA 200500054A EA 200500054 A EA200500054 A EA 200500054A EA 200500054 A1 EA200500054 A1 EA 200500054A1
Authority
EA
Eurasian Patent Office
Prior art keywords
obesity
treatment
disorders
nervous system
central nervous
Prior art date
Application number
EA200500054A
Other languages
Russian (ru)
Other versions
EA008835B1 (en
Inventor
Гари Йоханссон
Анника Йенмальм-Йенсен
Катарина Бейерлейн
Original Assignee
Биовитрум Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201925A external-priority patent/SE0201925D0/en
Priority claimed from SE0202181A external-priority patent/SE0202181D0/en
Priority claimed from SE0202908A external-priority patent/SE0202908D0/en
Priority claimed from SE0300357A external-priority patent/SE0300357D0/en
Application filed by Биовитрум Аб filed Critical Биовитрум Аб
Publication of EA200500054A1 publication Critical patent/EA200500054A1/en
Publication of EA008835B1 publication Critical patent/EA008835B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Данное изобретение относится к соединениям общей формулы (I), где P представляет собой сульфон или сульфонамид и A, B, W, X, Y и Rимеют значения, определенные в описании; к фармацевтическим композициям, включающим данные соединения, и к применению соединений для профилактики и лечения медицинских состояний, связанных с ожирением, сахарным диабетом II типа и/или расстройством ЦНС, для достижения снижения массы тела и повышения массы тела.Международная заявка была опубликована вместе с отчетом о международном поиске.This invention relates to compounds of the general formula (I), where P is a sulfone or sulfonamide, and A, B, W, X, Y and R have the meanings given in the description; to pharmaceutical compositions including these compounds and to the use of compounds for the prevention and treatment of medical conditions associated with obesity, type II diabetes and / or CNS disorder to achieve weight loss and weight gain. The international application was published with the report about international search.

EA200500054A 2002-06-20 2003-06-19 Substituted sulfone and sulfonamides and pharmaceutical compositions based thereon useful for the treatment of obesity, type ii diabetes cns disorders EA008835B1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
SE0201925A SE0201925D0 (en) 2002-06-20 2002-06-20 New compounds
SE0202181A SE0202181D0 (en) 2002-07-11 2002-07-11 New compounds
US40612002P 2002-08-26 2002-08-26
SE0202908A SE0202908D0 (en) 2002-10-01 2002-10-01 New compounds
US43401002P 2002-12-17 2002-12-17
SE0300357A SE0300357D0 (en) 2003-02-10 2003-02-10 New compounds
US46470103P 2003-04-23 2003-04-23
PCT/SE2003/001061 WO2004000828A1 (en) 2002-06-20 2003-06-19 New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Publications (2)

Publication Number Publication Date
EA200500054A1 true EA200500054A1 (en) 2005-06-30
EA008835B1 EA008835B1 (en) 2007-08-31

Family

ID=30004107

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200600975A EA011581B1 (en) 2002-06-20 2003-06-19 Heterocyclic compounds useful for the treatment of obesity and cns disorders
EA200500054A EA008835B1 (en) 2002-06-20 2003-06-19 Substituted sulfone and sulfonamides and pharmaceutical compositions based thereon useful for the treatment of obesity, type ii diabetes cns disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200600975A EA011581B1 (en) 2002-06-20 2003-06-19 Heterocyclic compounds useful for the treatment of obesity and cns disorders

Country Status (13)

Country Link
EP (1) EP1513828A1 (en)
CN (1) CN1662521A (en)
AU (1) AU2003243091A1 (en)
BR (1) BR0311952A (en)
CA (1) CA2486989A1 (en)
EA (2) EA011581B1 (en)
IL (1) IL165051A0 (en)
MX (1) MXPA04012914A (en)
NO (1) NO20050294L (en)
NZ (3) NZ552283A (en)
RS (1) RS111204A (en)
SG (1) SG156524A1 (en)
WO (1) WO2004000828A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1956004E (en) 2002-03-27 2012-08-31 Glaxo Group Ltd Quinoline derivatives and their use as 5-ht6 ligands
SE0301446D0 (en) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
EP1558582B1 (en) 2003-07-22 2005-12-21 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
SE0302760D0 (en) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
CA2545506A1 (en) * 2003-12-19 2005-06-30 Biovitrum Ab Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder
SE0303480D0 (en) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
CA2563895C (en) * 2004-04-13 2012-10-16 Synta Pharmaceuticals Corp. Disalt inhibitors of il-12 production
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
AR054044A1 (en) * 2005-05-23 2007-05-30 Astrazeneca Ab CHROMAN AND TETRAHYDRONAFTALENE DERIVATIVES AS RECEPTOR MODULATORS 5 - HT6; INTERMEDIARIES IN THEIR PREPARATION; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPELO IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CNS AND OBESITY DISEASES.
US7582767B2 (en) 2005-06-17 2009-09-01 Biovitrum Ab (Publ.) Substituted sulphonamide compound and uses thereof
EP1907384A2 (en) * 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
GEP20115199B (en) 2005-10-07 2011-04-11 Exelixis Inc Phosphatidylinositol 3-kinase inhibitors and their use
CN101300246A (en) 2005-11-03 2008-11-05 弗·哈夫曼-拉罗切有限公司 Arylsulfonylchromans as 5-HT6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
UY30048A1 (en) 2005-12-23 2007-07-31 Astrazeneca Ab SUBSTITUTED DERIVATIVES OF THE N, 2- (1H-BENZIMIDAZOL-1-IL) ACETAMIDE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
KR101060451B1 (en) 2006-06-20 2011-08-29 에프. 호프만-라 로슈 아게 Arylsulfonyl naphthalene derivatives and uses thereof
CA2653758A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof
WO2007147762A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonamidyl tetralin derivatives and uses thereof
TWI433839B (en) 2006-08-11 2014-04-11 Neomed Inst New benzimidazole derivatives 290
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US7888662B2 (en) 2008-06-20 2011-02-15 Varian Semiconductor Equipment Associates, Inc. Ion source cleaning method and apparatus
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
CA2834745A1 (en) * 2011-05-09 2012-11-15 Forma Tm, Llc Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
EP3083588B1 (en) 2013-12-20 2020-12-09 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
KR20180022792A (en) 2015-06-12 2018-03-06 엑소반트 사이언시즈 게엠베하 Diaryl and aryl heteroaryl urea derivatives useful for the prevention and treatment of sleep-disordered sleep disorders
CN108472285A (en) 2015-07-15 2018-08-31 阿速万科学有限责任公司 Diaryl for preventing and treating illusion associated with neurodegenerative disease and aryl heteroaryl urea derivative
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB947606A (en) * 1961-04-10 1964-01-22 Ici Ltd N-substituted piperazines
US4808595A (en) * 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
PT689536E (en) * 1993-03-16 2001-11-30 Pfizer NAFTALENE DERIVATIVES
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
DZ2376A1 (en) * 1996-12-19 2002-12-28 Smithkline Beecham Plc New sulfonamide derivatives process for their preparation and pharmaceutical compositions containing them.
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
AU1542201A (en) * 1999-11-05 2001-05-14 Nps Allelix Corp. Compounds having 5-HT6 receptor antagonist activity
EP1278744A1 (en) * 2000-05-05 2003-01-29 Millenium Pharmaceuticals, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
US6943174B2 (en) * 2000-06-14 2005-09-13 Warner-Lambert Company 6,5-Fused bicyclic heterocycles
IL154685A0 (en) * 2000-10-20 2003-09-17 Biovitrum Ab 2-,3-,4-, or 5-substituted-n1-(benzensulfonyl) indoles and their use in therapy
IL158593A0 (en) * 2001-05-11 2004-05-12 Biovitrum Ab Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
DE60218037T2 (en) * 2001-06-07 2007-08-23 F. Hoffmann-La Roche Ag NEW INDOIND DERIVATIVES WITH AFFINITY TO THE 5-HT6 RECEPTOR
YU98003A (en) * 2001-06-11 2006-03-03 Biovitrum Ab. Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes

Also Published As

Publication number Publication date
MXPA04012914A (en) 2005-03-31
EP1513828A1 (en) 2005-03-16
EA200600975A1 (en) 2006-10-27
CN1662521A (en) 2005-08-31
NZ536600A (en) 2007-08-31
CA2486989A1 (en) 2003-12-31
WO2004000828A1 (en) 2003-12-31
SG156524A1 (en) 2009-11-26
NO20050294L (en) 2005-02-04
IL165051A0 (en) 2005-12-18
EA008835B1 (en) 2007-08-31
AU2003243091A1 (en) 2004-01-06
RS111204A (en) 2006-12-15
NZ552282A (en) 2008-07-31
BR0311952A (en) 2005-04-19
EA011581B1 (en) 2009-04-28
NZ552283A (en) 2008-07-31

Similar Documents

Publication Publication Date Title
EA200500054A1 (en) NEW CONNECTIONS APPLICABLE FOR THE TREATMENT OF OBESITY, DIABETES MELLITUS TYPE II AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM
EA200301232A1 (en) NEW ARYL SULPHONAMIDE CONNECTIONS AND THEIR APPLICATION FOR TREATMENT OF OBESITY, TYPE II DIABETES AND CENTRAL NERVOUS DISORDERS
MXPA03011083A (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes.
SE0403006D0 (en) New compounds
EA199900669A1 (en) INTERMEDIATE COMPOUNDS FOR OBTAINING N-[AMINOIMINOMETHYL OR AMINOMETHYL-PHENYL] SUBSTITUTED PROPYLAMIDES
EA199900239A1 (en) SUBSTITUTED N- [AMINOIMINOMETHYL OR AMINOMETHYL) PHENYL] PROPYLAMIDES
EA200700035A1 (en) SULPHATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DI SORDERS
SE0302760D0 (en) New compounds
EA200301142A1 (en) DERIVATIVES OF HETEROCYCLILOXY-, -TIOOXY-AND-AMINOBENZAZOL AS A LYHANDS OF 5-HYDROXITRIPTAMINE-6
EA200600048A1 (en) BENZAZEPIN DERIVATIVES USED TO TREAT DISEASES ASSOCIATED WITH 5-HT RECEPTOR
NO20071560L (en) Vasopressin v1a antagonists.
ES2060951T3 (en) AZAINDENOS.
EA200300528A1 (en) 1-ARYL-OR 1-ALKYLSULPHONYLETHETROCYCLYLBENZAZOLES AS LIGANDS 5-HYDROXITRIPTAMINE-6
MA33209B1 (en) INHIBITORS OF HEPATITIS C VIRUS REPLICATION
SE0302232D0 (en) Novel Compounds
NO20032861L (en) Heterory urea neuropeptide Y Y5 receptor antagonists
NO20063761L (en) Sulfonamide derivatives for the treatment of diseases
DK1735296T3 (en) Materials and methods for treating coagulation disorders
EA200300716A1 (en) HETEROCYCLILALKILINDOL OR-ASAINDOL COMPOUNDS AS LIGAND 5-HYDROXYTRIPTAMINE-6
EA200601194A1 (en) NEW DERIVATIVES OF BENZOFURANE USED FOR THE PREVENTION OR TREATMENT OF DISTURBANCES ASSOCIATED WITH 5-HT-RECEPTOR
EA200600071A1 (en) Derivatives of N-phenylpyrazine and Methods for the Prevention or Treatment of Diseases Associated with 5HT-Receptor
NO20014241D0 (en) C16-unsaturated FP-selective prostaglandin analogs
DE602004025119D1 (en) NEW DERIVATIVES OF 4,4'-DITHIOBIS- (3-AMINOBUTAN-1-SULPHONATE) AND COMPOSITIONS CONTAINING THEREOF
NO20065958L (en) Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1 / CB2 receptor subtype selectivity
TW200510354A (en) Benzoxazinone-derived sulphonamide compounds, their preparation and use as medicaments

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU